UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Richard Mamelok, M.d, M.D | Internal Medicine | Palo Alto, CA | $6,400 | $0 |
| Malcolm Fraser, Md, MD | Geriatric Medicine | Brooksville, FL | $6,264 | $0 |
| Sagar Shah, Md, MD | Urology | Jacksonville, FL | $6,204 | $0 |
| Kathryn Copeland, Md, MD | Obstetrics & Gynecology | Carmel, IN | $5,903 | $0 |
| Elizabeth Bozeman, Md, MD | Urology | Florence, SC | $5,577 | $0 |
| Vincent Lucente, M.d, M.D | Urogynecology and Reconstructive Pelvic Surgery | Allentown, PA | $5,568 | $0 |
| Carolyn Stahlhut, Msn, Crnp, Cunp, MSN, CRNP, CUNP | Adult Health | Lansdale, PA | $4,933 | $0 |
| Matthew Hoggatt, Md, MD | Urology | Webster, TX | $4,436 | $0 |
| Gary Lemack, Md, MD | Urology | Dallas, TX | $4,336 | $0 |
| Dr. Adolphus Lewis, Do, DO | Family Medicine | Fort Worth, TX | $4,180 | $0 |
| Nitya Abraham, M.d, M.D | Urogynecology and Reconstructive Pelvic Surgery | Bronx, NY | $4,075 | $0 |
| Mrs. Amanda Maggart, Pa-C, PA-C | Physician Assistant | Worthington, OH | $3,775 | $0 |
| Mickey Karram, M.d, M.D | Obstetrics & Gynecology | West Chester, OH | $3,690 | $0 |
| Andrew Graf | Internal Medicine | Plymouth Meeting, PA | $3,518 | $0 |
| Mrs. Elizabeth Williams, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | Saint Louis, MO | $3,435 | $0 |
| Shervin Mortazavi, M.d, M.D | Internal Medicine | Bronx, NY | $3,258 | $0 |
| Bradley Gill, M.d, M.D | Urology | Mayfield Heights, OH | $3,230 | $0 |
| Roger Dmochowski, Md, MD | Urology | Nashville, TN | $3,160 | $0 |
| Shammona Clark, Fnp-C, FNP-C | Family | Chicago, IL | $2,864 | $0 |
| Daniel Furlong, M.d, M.D | Urology | Charleston, SC | $2,800 | $0 |
| Ekene Enemchukwu, Md, MD | Urology | Stanford, CA | $2,426 | $0 |
| Scott Young, Pa, PA | Medical | Phoenix, AZ | $2,344 | $0 |
| David Smith, M.d, M.D | Geriatric Medicine | Brownwood, TX | $2,189 | $0 |
| Michael Ingber, M.d, M.D | Urology | Denville, NJ | $2,120 | $0 |
| Diana Londono, Md, MD | Urology | Glendora, CA | $2,120 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.